VivoSeq
Musculoskeletal

Femur Fracture

22

Pipeline Programs

2

Active Trials

12

Companies Involved

Femur Fracture is an emerging landscape with 22 programs across 12 companies. The most active players are EMD Serono, TLC Biopharmaceuticals, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd.. 5 therapies are approved with 1 more in late-stage development.

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

46/100

Attrition Rate

32/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

93%

Small molecule

26 of 28 classified programs — the dominant modality here.

7%ALL OTHERSPeptide27%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 100% of 28 pipeline programs.

Trial Status

22

clinical trials

Unknown status7 · 32%
Completed6 · 27%
Terminated5 · 23%
Withdrawn2 · 9%
Enrolling by invitation1 · 5%
Recruiting1 · 5%

Trial Activity

22 trials

Supracondylar Distal Femur Fractures and Abaloparatide
Withdrawn··Phase 4·NCT04626141
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)